Active AR signaling is central to prostate cancer development and progression; aberrant activation of AR signaling including expression of AR splice variants (AR-V) mediates clinical resistance to androgen deprivation therapy and to second-generation potent ARPis such as abiraterone and enzalutamide5,18. Here, AR is linked to prostate cancer.